{
  "Variants Include": [
    {
      "Gene": "PINK1",
      "variants": [
        {
          "hgvs": "c.1060G>A",
          "protein_change": "p.G354R",
          "description": "The c.1060G>A (p.G354R) mutation was shown to significantly reduce PINK1 kinase activity, leading to impaired mitophagy and increased neuronal cell death."
        }
      ]
    },
    {
      "Gene": "LRRK2",
      "variants": [
        {
          "hgvs": "c.1922G>A",
          "protein_change": "p.R641Q",
          "description": "The c.1922G>A (p.R641Q) variant was associated with increased kinase activity and neurotoxicity in dopaminergic neurons."
        },
        {
          "hgvs": "c.1436C>T",
          "protein_change": "p.S479F",
          "description": "The c.1436C>T (p.S479F) mutation enhanced LRRK2 kinase activity and promoted α-synuclein aggregation in cellular models."
        },
        {
          "hgvs": "c.1606G>A",
          "protein_change": "p.G536R",
          "description": "The c.1606G>A (p.G536R) variant increased LRRK2 auto-phosphorylation and led to mitochondrial dysfunction in PD patient-derived neurons."
        }
      ]
    },
    {
      "Gene": "PARK2",
      "variants": [
        {
          "hgvs": "c.661C>T",
          "protein_change": "p.R221W",
          "description": "The c.661C>T (p.R221W) mutation impaired PARK2 ubiquitin ligase activity, resulting in reduced proteasomal degradation of damaged mitochondria."
        }
      ]
    },
    {
      "Gene": "SNCA",
      "variants": [
        {
          "hgvs": "c.241G>A",
          "protein_change": "p.G81R",
          "description": "The c.241G>A (p.G81R) variant enhanced α-synuclein oligomerization and increased toxicity in dopaminergic neurons."
        },
        {
          "hgvs": "c.271C>T",
          "protein_change": "p.R91C",
          "description": "The c.271C>T (p.R91C) mutation promoted α-synuclein fibril formation and disrupted synaptic vesicle trafficking."
        },
        {
          "hgvs": "c.307G>A",
          "protein_change": "p.G103R",
          "description": "The c.307G>A (p.G103R) variant increased α-synuclein aggregation and impaired lysosomal function in cellular models."
        }
      ]
    },
    {
      "Gene": "GBA",
      "variants": [
        {
          "hgvs": "c.109G>A",
          "protein_change": "p.G37R",
          "description": "The c.109G>A (p.G37R) mutation reduced GBA enzyme activity and elevated α-synuclein levels in patient-derived fibroblasts."
        },
        {
          "hgvs": "c.154G>A",
          "protein_change": "p.G52R",
          "description": "The c.154G>A (p.G52R) variant impaired GBA catalytic function and increased lipid accumulation in macrophages."
        }
      ]
    }
  ],
  "Disease": {
    "name": "Parkinson's disease",
    "mondo_term": "MONDO:0005223"
  },
  "Experiment Methods": [
    {
      "method": "Kinase activity assays",
      "materials_used": "HEK293 cells overexpressing PINK1 variants",
      "readout_type": "Quantitative ( kinase activity measurement )",
      "replicates": "3 biological replicates",
      "controls": "Wild-type PINK1-expressing cells",
      "statistical_methods": "ANOVA with post-hoc Tukey tests",
      "conclusion": "Abnormal",
      "molecular_effect": "Partial loss-of-function",
      "result_description": "Reduced PINK1 kinase activity, leading to impaired mitophagy and increased neuronal cell death."
    },
    {
      "method": "Cell culture models",
      "materials_used": "SH-SY5Y cells expressing LRRK2 variants",
      "readout_type": "Quantitative ( kinase activity and α-synuclein aggregation )",
      "replicates": "N.D.",
      "controls": "N.D.",
      "statistical_methods": "N.D.",
      "conclusion": "Abnormal",
      "molecular_effect": "Gain-of-function",
      "result_description": "Increased kinase activity and neurotoxicity in dopaminergic neurons."
    },
    {
      "method": "Ubiquitin ligase assays",
      "materials_used": "Primary neurons from PARK2 mutation carriers",
      "readout_type": "Quantitative ( proteasomal degradation of mitochondrial proteins )",
      "replicates": "N.D.",
      "controls": "N.D.",
      "statistical_methods": "N.D.",
      "conclusion": "Abnormal",
      "molecular_effect": "Loss-of-function",
      "result_description": "Impaired PARK2 ubiquitin ligase activity, resulting in reduced proteasomal degradation of damaged mitochondria."
    },
    {
      "method": "Cellular toxicity assays",
      "materials_used": "SNCA variant-expressing dopaminergic neurons",
      "readout_type": "Quantitative ( cell viability and α-synuclein oligomerization )",
      "replicates": "N.D.",
      "controls": "N.D.",
      "statistical_methods": "N.D.",
      "conclusion": "Abnormal",
      "molecular_effect": "Gain-of-function",
      "result_description": "Enhanced α-synuclein oligomerization and increased toxicity in dopaminergic neurons."
    },
    {
      "method": "Enzymatic activity assays",
      "materials_used": "GBA variant-expressing fibroblasts",
      "readout_type": "Quantitative ( GBA enzyme activity and α-synuclein levels )",
      "replicates": "N.D.",
      "controls": "N.D.",
      "statistical_methods": "N.D.",
      "conclusion": "Abnormal",
      "molecular_effect": "Loss-of-function",
      "result_description": "Reduced GBA enzyme activity and elevated α-synuclein levels in patient-derived fibroblasts."
    }
  ]
}